Methylene Blue And Mitochondria — The Dye Being Studied For Brain Energy
Quick Read Methylene blue is a 160-year-old dye now being studied for its effects on brain energy production. Your brain
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Benfotiamine is a fat-soluble form of vitamin B1 that reaches the brain far more effectively than regular B1 supplements. Your brain relies on B1 to convert glucose into usable energy, and when this process fails, brain cells struggle to function. Standard B1 is water-based and cannot easily cross the fatty barriers that protect brain cells, but benfotiamine’s chemical structure allows it to pass through these barriers and boost energy production where it matters most.
Animal studies consistently show benfotiamine reduces amyloid plaques and tau tangles, the hallmark damage of Alzheimer’s disease, while also reducing inflammation and oxidative stress. A small human trial of 70 people with mild cognitive impairment or early Alzheimer’s found that benfotiamine reduced cognitive decline by 43% and slowed disease worsening by 77%, though results were mixed across different measures. A larger trial of 406 people is currently underway and will provide clearer answers about whether these benefits hold up in humans.
Benfotiamine has been proven safe at doses up to 1,200 mg with no serious adverse effects reported. The human evidence is still early and the animal data may not predict real-world results, but the scientific foundation is unusually solid for a supplement. A 300 mg daily dose appears to be both safe and the best-studied amount in humans.
Verdict: Benfotiamine has genuine scientific momentum behind it and is worth watching, particularly for people serious about brain health, though definitive proof awaits results from the ongoing large-scale trial.
What if one of the most promising supplements for protecting the ageing brain wasn’t a newly discovered exotic compound, but a smarter version of a vitamin you’ve had access to for decades? Vitamin B1, thiamine, has been essential to human metabolism since long before we ever measured it in a lab. But here’s the thing most people don’t know: standard thiamine supplements are poorly absorbed, and the version your brain is actually crying out for barely makes it through the gut wall. Benfotiamine is different. It’s a fat-soluble, synthetic form of B1 that crosses into cells, including brain cells, far more efficiently than plain thiamine. And right now, it’s sitting at the centre of a 406-person, Phase 2 randomised controlled trial for early Alzheimer’s disease. That’s not the story of a wellness trend. That’s the story of a molecule scientists are taking seriously enough to stake a proper clinical trial on. Here’s what the research actually says, and what it doesn’t.
To understand why benfotiamine matters, you first need to understand what thiamine (vitamin B1) does in your brain, and why getting enough of it there is harder than it sounds.
Thiamine is critical for energy metabolism. Your brain runs almost entirely on glucose, and thiamine-dependent enzymes are the workhorses that convert that glucose into usable energy. When thiamine-dependent processes falter, brain cells struggle to generate enough energy to function and survive. It’s not dramatic, it’s a slow, quiet decline [2].
Here’s the problem with regular thiamine: it’s water-soluble, which means it doesn’t pass easily through fat-rich cell membranes. The brain is one of the fattiest organs in the body. Standard thiamine supplements taken orally produce only modest increases in brain thiamine levels [6]. Clinical trials of regular thiamine in Alzheimer’s patients have shown very little benefit, not necessarily because thiamine doesn’t matter, but because plain thiamine can’t get where it’s needed [7].
Benfotiamine (often abbreviated as BFT) is what scientists call a “thioester”, a fat-soluble prodrug of thiamine. Because it’s lipid-soluble, it passes through cell membranes far more readily. Once inside, it’s converted into thiamine diphosphate (ThDP), the active coenzyme form. Studies confirm that benfotiamine supplementation significantly increases ThDP concentrations in the hippocampus and other key brain regions [10].
But here’s where it gets interesting: researchers have found that benfotiamine’s brain benefits go well beyond simply boosting thiamine levels. It appears to have its own distinct biological actions, suppressing a problematic enzyme called GSK-3β (glycogen synthase kinase-3 beta), reducing oxidative stress, blocking the formation of advanced glycation end-products (AGEs, the damaging compounds that build up when sugar reacts with proteins), and dampening neuroinflammation [3, 6]. These effects seem to operate through mechanisms entirely separate from its role as a thiamine precursor. That’s unusual, and it’s one reason researchers find benfotiamine so compelling.
One of the foundational questions about any brain-targeted supplement is simple: does it actually get to the brain? For benfotiamine, a 2020 rat study published in *Experimental Gerontology* gave a clear answer [10].
Researchers used a well-established rat model of sporadic Alzheimer’s disease, induced by injecting streptozotocin (STZ) directly into the brain, which disrupts insulin signalling and glucose metabolism in a way that mimics early-stage AD. Rats supplemented with 150 mg/kg of benfotiamine for 30 days showed significantly increased thiamine diphosphate concentrations in both the hippocampus and entorhinal cortex, two regions central to memory formation and among the first to deteriorate in Alzheimer’s disease.
Beyond that, benfotiamine improved the function of mitochondrial enzymes (the energy-producing machinery inside cells), improved insulin signalling pathways, inactivated GSK-3α/β and ERK1/2 (two enzymes that trigger the tau protein tangles associated with AD), and reduced inflammation. Cognitive performance in maze tests also improved. The authors concluded that benfotiamine’s ability to physically reach the brain and increase ThDP at tissue level is the essential first step that plain thiamine fails at [10].
Evidence grade: Early stage, these are animal studies. Important mechanistic evidence, but human replication is needed.
What makes benfotiamine unusually interesting scientifically is that it doesn’t just do one thing. A 2023 review in the *International Journal of Molecular Sciences* summarised the breadth of its actions [2]:
– It reduces amyloid-β plaque formation (the plaques that clog the Alzheimer brain) – It reduces tau phosphorylation (the tangled protein structures that kill neurons) – It decreases oxidative stress – It suppresses neuroinflammation – It protects mitochondrial function – It blocks the formation of advanced glycation end-products (AGEs) – It modulates insulin signalling in the brain
This multi-pathway action was reinforced by a 2010 mouse study published in *Brain* that remains one of the most cited pieces of preclinical evidence [7]. Researchers used APP/PS1 transgenic mice, a genetic mouse model of AD, and treated them with benfotiamine for eight weeks. The results were striking: benfotiamine dose-dependently improved spatial memory in the Morris water maze test, significantly reduced amyloid plaque numbers in cortical brain regions, and lowered phosphorylated tau levels.
Critically, the researchers compared benfotiamine to another fat-soluble thiamine derivative called fursultiamine. Both compounds increased brain thiamine levels equally, but only benfotiamine reduced amyloid plaques and phosphorylated tau, and only benfotiamine elevated the phosphorylation (inactivation) of GSK-3α and GSK-3β. This strongly suggests benfotiamine has protective effects that are independent of thiamine itself, something unique to its molecular structure [7].
Evidence grade: Early stage, robust animal data across multiple models, but these are not human trials.
This is where benfotiamine moves from “interesting lab compound” to “something worth paying serious attention to.”
A Phase IIa randomised, double-blind, placebo-controlled clinical trial published in the *Journal of Alzheimer’s Disease* in 2020 tested 12 months of benfotiamine treatment in 70 people with either amnestic mild cognitive impairment (aMCI) or mild dementia due to Alzheimer’s disease [12]. This is the trial that should be on your radar.
The headline findings:
– ADAS-Cog (a standard cognitive assessment scale, higher scores mean more impairment): cognitive decline was 43% lower in the benfotiamine group compared to placebo, though this did not reach statistical significance (p = 0.125) – CDR-Sum of Boxes (a clinician-rated dementia severity scale): worsening was 77% lower in the benfotiamine group, and this was statistically significant (p = 0.034) – Advanced glycation end-products (AGEs) in blood were significantly reduced in the benfotiamine group (p = 0.044) – Brain FDG-PET (which measures glucose metabolism in the brain, a key biomarker for AD): exploratory analysis showed a treatment effect at 12 months (p = 0.002)
The effect on CDR scores was notably stronger in people who did not carry the APOEε4 gene variant, a genetic risk factor for Alzheimer’s. This suggests benfotiamine may work differently depending on genetic background, which researchers are now investigating further [12].
Benfotiamine was safe and well-tolerated. No serious adverse effects were reported.
Evidence grade: Promising, a proper randomised controlled trial in humans with meaningful effect sizes. But it’s a small trial (70 people, one year), and the primary cognitive outcome did not reach statistical significance. It’s encouraging, not conclusive.
Alongside the Phase IIa RCT, a small observational study published in *Neuroscience Bulletin* in 2016 added an intriguing data point [13].
Five patients with mild to moderate Alzheimer’s disease were given 300 mg of oral benfotiamine daily for 18 months. All five showed PET scan evidence of amyloid-β deposition at baseline. The results:
– All five patients improved on the Mini-Mental Status Examination (MMSE, the standard brief cognitive test), with an average improvement of 3.2 points at 18 months. For context, untreated AD patients typically decline by 2-4 points per year on MMSE. – Three patients received follow-up PiB-PET amyloid imaging: they showed a 36.7% increase in amyloid deposition in the brain, and yet their MMSE scores still improved by an average of 3 points.
This last finding is particularly thought-provoking. The amyloid continued to accumulate, but cognitive function improved anyway. This suggests benfotiamine may be helping patients function better despite ongoing disease progression, possibly by improving energy metabolism, reducing inflammation, or preserving synaptic function, rather than by clearing amyloid directly [13].
It’s an intriguing observation, but with only five patients this is entirely preliminary. Treat it as hypothesis-generating, not conclusive.
Evidence grade: Early stage in humans, n=5, no control group. Important signal, but far too small to draw conclusions from.
Before a supplement can be taken seriously as a therapeutic candidate, it needs a robust safety profile. A Phase I randomised, double-blind, placebo-controlled trial published in *Drug Design, Development and Therapy* in 2021 systematically assessed benfotiamine’s safety and pharmacokinetics across single doses from 150 mg up to 1,200 mg, and multiple ascending doses [14].
Key findings:
– Benfotiamine was safe and well-tolerated at all doses tested, up to 1,200 mg single dose – Both single and multiple ascending dose studies showed no serious adverse events – Thiamine and thiamine diphosphate showed moderate accumulation in blood with repeated dosing, meaning consistent supplementation does build up tissue levels, which is what you want
This matters enormously for the current Phase 2B trial, which is testing doses of 600 mg and 1,200 mg in 406 people with early Alzheimer’s disease over 72 weeks [4]. Knowing the safety ceiling was established in a proper Phase I study gives that larger trial a solid foundation.
Evidence grade: Strong for safety, this is exactly the kind of well-designed Phase I data that drug development requires.
The most important thing happening in benfotiamine research right now is the BenfoTeam trial, registered on ClinicalTrials.gov (NCT06223360) in January 2024 [4, 15].
This is a seamless Phase 2A/2B randomised, double-blind, placebo-controlled trial in 406 participants with early Alzheimer’s disease. Here’s how it works:
– Phase 2A (roughly 150 enrollees): determines whether 600 mg or 1,200 mg/day is the highest safe and tolerable dose to carry forward – Phase 2B (the full 406): assesses efficacy and longer-term safety at the selected dose over 72 weeks (nearly 18 months) – Primary efficacy measures: CDR-Sum of Boxes (clinician-rated dementia staging) and ADAS-Cog13 (cognitive assessment), the two gold-standard clinical endpoints – Secondary measures include MoCA (Montreal Cognitive Assessment), daily living abilities, pharmacokinetic measures of thiamine, and erythrocyte transketolase activity as a blood biomarker of whether the drug is actually working
The trial protocol notes that benfotiamine may have “additive or synergistic effects” when used alongside amyloid-targeting therapies, a genuinely novel angle in Alzheimer’s treatment thinking [4].
This is a serious, properly powered trial. If it shows meaningful results, benfotiamine could shift from “promising supplement” to “evidence-based clinical intervention” in short order.
Let’s be honest about the limits of what we have.
Most of the mechanistic evidence is from animals. The studies involving rats and transgenic mice are genuinely illuminating, consistent, mechanistically coherent, and replicated across multiple research groups, but animal models of Alzheimer’s have a poor track record of predicting what works in humans. Many drugs that looked extraordinary in mice have failed in human trials. We cannot assume benfotiamine will be an exception until we have the human data [7, 1, 10].
The human trial that showed results was small. Seventy people over 12 months is encouraging, not definitive. The primary cognitive outcome (ADAS-Cog) did not reach statistical significance, even if the CDR endpoint did. Researchers are careful to call these results “potentially efficacious” rather than proven [12].
The 5-patient observational study is essentially anecdote. It’s fascinating, particularly the observation that cognition improved despite continued amyloid accumulation, but with n=5 and no control group, it tells us very little with statistical certainty [13].
We don’t fully understand the mechanism. Researchers know benfotiamine does more than boost thiamine levels, but the exact molecular pathways responsible for its apparent neuroprotective effects beyond ThDP conversion remain to be identified. The review literature is candid about this [2, 6].
We don’t know the optimal dose for brain health. The Phase I trial confirmed safety up to 1,200 mg. The small human clinical study used 300 mg daily. The BenfoTeam trial is testing 600 mg and 1,200 mg. The dose-response relationship in humans for cognitive outcomes is genuinely unknown [12, 13, 14].
We don’t know whether it prevents Alzheimer’s in healthy people. Every human trial to date has been conducted in people with existing MCI or Alzheimer’s diagnosis. Whether benfotiamine could meaningfully reduce risk in cognitively healthy adults is an open question [4].
Results may vary by genetics. The Phase IIa trial found the CDR and AGE effects were stronger in APOEε4 non-carriers. This is a real signal that deserves investigation, but for now, we don’t know enough to say who benefits most [12].
Here’s what a sensible, informed person should make of all this.
Benfotiamine is not a proven treatment for Alzheimer’s disease. That conclusion would be premature. But it’s also not your average wellness supplement with a thin evidence base and a lot of marketing behind it. This is a molecule with a coherent biological rationale, a consistent body of preclinical evidence across multiple animal models, a proper Phase IIa randomised controlled trial showing meaningful signals, particularly a 77% reduction in CDR worsening, and a large Phase 2B trial now underway.
That’s a meaningful evidence trajectory. This is a supplement in momentum.
For healthy adults in their 40s, 50s and 60s who are serious about brain health, here’s the practical logic:
Benfotiamine is a B vitamin derivative. B vitamins are water-soluble. In benfotiamine’s case, it behaves similarly to a fat-soluble compound before conversion, but its metabolites are excreted normally and no accumulation toxicity has been identified at any dose tested to date, including 1,200 mg in Phase I trials [14]. It has no known adverse effects at therapeutic doses [2, 6]. The safety profile is genuinely reassuring.
Thiamine deficiency is not rare. It’s associated with alcohol use, a diet high in refined carbohydrates, poor gut absorption (which increases with age), and certain medications. Sub-optimal thiamine status may be more common in older adults than we recognise, and it quietly undermines the exact energy-metabolism processes benfotiamine is designed to support [3].
The dose used in the human trial was 300 mg daily [13]. The larger ongoing trial is testing 600–1,200 mg. Most commercially available benfotiamine supplements are typically in the 150–300 mg range. A 300 mg daily dose is both the best-studied human dose and within normal supplement territory.
A sensible approach: If you’re in the 40-65 age bracket and brain health is a genuine priority, benfotiamine is one of the more scientifically credible additions to a brain health stack. The risk-benefit calculation, an excellent safety record, no known adverse effects, a plausible mechanism, and early human signals worth watching, supports supplementation at 300 mg daily while we wait for the BenfoTeam results. You’re not gambling. You’re making a well-reasoned bet on emerging science that already has more going for it than most supplements on the shelf.
Watch the BenfoTeam trial results. They may change things significantly, in either direction.
At Vitacuity, we read over 1.77 million research papers to identify the compounds that are genuinely worth your attention. Benfotiamine earned its place on that list.
[1] Exploring the Therapeutic Potential of Benfotiamine in a Sporadic Alzheimer’s-Like Disease Rat Model: Insights into Insulin Signaling and Cognitive Function (2024). DOI: 10.1021/acschemneuro.4c00113 | https://pubmed.ncbi.nlm.nih.gov/39007352/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342302/
[2] Synthetic Thioesters of Thiamine: Promising Tools for Slowing Progression of Neurodegenerative Diseases (2023). *International Journal of Molecular Sciences.* DOI: 10.3390/ijms241411296 | https://pubmed.ncbi.nlm.nih.gov/37511056/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379298/
[3] Potential of Benfotiamine in the Treatment of Neuropsychological Disorders (2025). DOI: 10.1007/s11033-025-11198-4 | https://pubmed.ncbi.nlm.nih.gov/41160288/
[4] Protocol for a Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam) (2024). *PLOS ONE.* DOI: 10.1371/journal.pone.0302998 | https://pubmed.ncbi.nlm.nih.gov/38809849/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135745/
[5] Evaluation of Neuroprotective Role of Benfotiamine in Alzheimer’s Disease Model: A Randomized Control Study (2025). *Clinical Therapeutics.* DOI: 10.7417/CT.2025.5195 | https://pubmed.ncbi.nlm.nih.gov/40176579/
[6] Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine (2021). *International Journal of Molecular Sciences.* DOI: 10.3390/ijms22115418 | https://pubmed.ncbi.nlm.nih.gov/34063830/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196556/
[7] Powerful Beneficial Effects of Benfotiamine on Cognitive Impairment and Beta-Amyloid Deposition in Amyloid Precursor Protein/Presenilin-1 Transgenic Mice (2010). *Brain.* https://pubmed.ncbi.nlm.nih.gov/20385653/
[10] Oral Benfotiamine Reverts Cognitive Deficit and Increases Thiamine Diphosphate Levels in the Brain of a Rat Model of Neurodegeneration (2020). *Experimental Gerontology.* DOI: 10.1016/j.exger.2020.111097 | https://pubmed.ncbi.nlm.nih.gov/32987117/
[12] Benfotiamine and Cognitive Decline in Alzheimer’s Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial (2020). *Journal of Alzheimer’s Disease.* DOI: 10.3233/JAD-200896 | https://pubmed.ncbi.nlm.nih.gov/33074237/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880246/
[13] Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease (2016). *Neuroscience Bulletin.* DOI: 10.1007/s12264-016-0067-0 | https://pubmed.ncbi.nlm.nih.gov/27696179/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567484/
[14] Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects (2021). *Drug Design, Development and Therapy.* DOI: 10.2147/DDDT.S296197 | https://pubmed.ncbi.nlm.nih.gov/33727798/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955752/
[15] Protocol for a Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam) (2024). *PLOS ONE.* DOI: 10.1371/journal.pone.0302998 | https://pubmed.ncbi.nlm.nih.gov/38809849/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135745/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Methylene blue is a 160-year-old dye now being studied for its effects on brain energy production. Your brain
Quick Read Vitamin E comes in two forms with very different molecular shapes. Natural vitamin E (labeled d-alpha-tocopherol) has one
The nutrients that matter, the forms that work, and the claims to ignore.
